在研主持项目包括：国家“万人计划”科技创新领军人才项目；国家自然科学基金委员会面上项目；医科院创新工程项目。

近5年代表性文章：

1. Li H#, Li J#, Li J, Li H, Wang X, Jiang J, Lei L,Sun H, Tang M, Dong B, He W, Si S, Hong B, Li Y, Song D, Peng Z*, Che Y*, Jiang JD*. Carrimycin inhibits coronavirusreplication by decreasing the efficiency of programmed –1 ribosomalframeshifting through directly binding to the RNA pseudoknot of viralframeshift-stimulatory element. Acta Pharmaceutica Sinica B, 2024Jun;14(6):2567-2580.

2. Li H#, Wang XK#, Tang M, Lei L, Li JR, Sun H,Jiang J, Dong B, Li HY, Jiang JD, PengZG*. Bacteroides thetaiotaomicron ameliorates mouse hepatic steatosisthrough regulating gut microbial composition, gut-liver folate and unsaturatedfatty acids metabolism. Gut Microbes, 2024Jan-Dec;16(1):2304159.

3. Zhu JY#, Tang M#, Li H, Shi YL, Li YM, Li YH, MaXC, Duan QL, Mei YH, He HW, Zhang N*, PengZG*, Song DQ. Design, synthesis and triglyceride-lowering activity of tricyclic matrinederivatives for the intervention of non-alcoholic fatty liver disease.BioorgChem. 2024 Jan:142:106925.

4. Li JY#, Zhong XL#, Li HY#, Yu ZH, LiJR, Duan QL, Li YH, Chen FB, Wang YX, Wu Y, Liu YH*, Peng ZG*, Song DQ*. Design, synthesis and biologicalevaluation of biaryl amide derivatives against SARS-CoV-2 with dual-target mechanism.EurJ Med Chem, 2024 Jan 15:264:115978.

5. Jiang J, Li H*, Tang M, Lei L, Li HY, Dong B, Li JR, Wang XK, Sun H, LiJY, Xu JC, Gong Y, Jiang JD, Peng ZG*.Upregulation of Hepatic Glutathione S-Transferase Alpha 1 Ameliorates MetabolicDysfunction-Associated Steatosis by Degrading Fatty Acid Binding Protein 1. Int JMol Sci. 2024 May 7;25(10):5086.

6. Li Y, Liu C, Han X, Sheng R, Bao L, Lei L, Wu Y, Li Q, Zhang Y, ZhangJ, Wang W, Zhang Y, Li S, Wang C, Wei X, Wang J, Peng Z*, Xu Y*, Si S*. The novel small molecule E0924Gdually regulates bone formation and bone resorption through activating thePPARδ signaling pathway to prevent bone loss in ovariectomized rats and senilemice. Bioorg Chem. 2024 Jun:147:107364. doi:10.1016/j.bioorg.2024.107364.

7. Hao X, Li S, Li J, Wang G, Li J, PengZ*, Gan M*. Acremosides A-G, Sugar Alcohol-Conjugated AcyclicSesquiterpenes from a Sponge-Derived Acremonium Species. J Nat Prod. 2024 Apr26;87(4):1059-1066.

8. Wang MX, Peng ZG*.17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fattyliver disease. Pharmacol Ther. 2023 Jun; 246:108428.

9. Sun H, Wang XK, Li JR, Tang M, Li H, Lei L, Li HY, Jiang J, Li JY, DongB, Jiang JD, Peng ZG*.Establishment and application of a high-throughput screening model for celladhesion inhibitors. Front Pharmacol. 2023 Feb23;14:1140163.

10. Liu Y, Li J, Gu Y, Ma L, Cen S*, PengZ*, Hu L*. Synthesis and structure-activity relationship studyof new biaryl amide derivatives and their inhibitory effects against hepatitisC virus. Eur J Med Chem. 2022 Jan 15; 228: 114033.

11. Wang Y#, Li J#, Tan J, Yang B, Quan Y, Peng Z*, Li Y*, Li Z. Design,Synthesis, and Biological Evaluation of2-((4-Bisarylmethyl-piperazin-1-yl)methyl)benzonitrile Derivatives as HCV EntryInhibitors. J Med Chem. 2022 Feb 10;65(3):2107-2121.

12. Li HY, Peng ZG*.Targeting lipophagy as a potential therapeutic strategy for nonalcoholic fattyliver disease. Biochem Pharmacol. 2022 Jan 31;197:114933.

13. Li H#, Liu NN#, Li JR, Dong B, Wang MX, Tan JL,Wang XK, Jiang J, Lei L, Li HY, Sun H, Jiang JD* and Peng ZG*. Combined Use of Bicyclol and Berberine AlleviatesMouse Nonalcoholic Fatty Liver Disease. Front Pharmacol. 2022 Feb 16;13:843872.

14. Li H#, Liu NN#, Li JR,Wang MX, Tan JL, Dong B, Lan P, Zhao LM, PengZG*, Jiang JD*. Bicyclol ameliorates advanced liver diseases in murinemodels via inhibiting the IL-6/STAT3 signaling pathway. Biomed Pharmacother, June2022, 150: 113083.

15. Wang M, Li J, Li H, Dong B, Jiang J, Liu N, Tan J, Wang X, Lei L, LiH, Sun H, Tang M, Wang H, Yan H, Li Y, Jiang J, Peng Z*. Down-regulating the high level of 17-beta-hydroxysteroiddehydrogenase 13 plays a therapeutic role for non-alcoholic fatty liver disease.IntJ Mol Sci, 2022 May 16, 23(10):5544.

16. Wang XK, Peng ZG*.Targeting Liver Sinusoidal Endothelial Cells: An Attractive TherapeuticStrategy to Control Inflammation in Nonalcoholic Fatty Liver Disease. FrontPharmacol. 2021 Apr 15;12:655557.

17. Zou LL, Li JR, Li H, Tan JL, Wang MX, Liu NN, Gao RM, Yan HY, Wang XK,Dong B, Li YH, Peng ZG*.TGF-β isoforms inhibit hepatitis C virus propagation in transforming growthfactor beta/SMAD protein signalling pathway dependent and independent manners. JCell Mol Med. 2021 Apr;25(7):3498-3510.

18. Jiang X#, Tan J#, Wang Y, Chen J, Li J, Jiang Z,Quan Y, Jin J, Li Y, Cen S, Li Y*, PengZ*, Li Z*. 2-((4-Arylpiperazin-1-yl)methyl)benzonitrileDerivatives as Orally Available Inhibitors of Hepatitis C Virus with a NovelMechanism of Action. J Med Chem. 2020 Jun11;63(11):5972-5989.

19. Lv XQ, Zou LL, Tan JL, Li H, Li JR, Liu NN, Dong B, Song DQ, Peng ZG*. Aloperine inhibits hepatitis C virusentry into cells by disturbing internalisation from endocytosis to the membranefusion process. Eur J Pharmacol.  2020Sep 15, 883：173323. doi:10.1016/j.ejphar.2020.173323.

20. Li H, Liu NN, Li JR, Wang MX, Tan JL, Zou LL, Dong B, Peng ZG*, Jiang JD*. Bifendateindirectly inhibits alanine transaminase release without direct interaction invitro and in vivo. Acta Pol Pharm. 2020,77(4): 629-635.

21. Li H, Liu NN, PengZG*. The effect of bicyclol on blood biomarkers of NAFLD: a systematicreview and meta-analysis. BMJ Open, 2020 Dec 4, 10(12): e039700.

22. Huang MH#, Li H#, Xue R, Li JR, Wang LH,ChengJJ, Wu ZY, Li WJ, Chen JH, Lv XQ, Li Q, Lan P, Zhao LM, Yang YF*, Peng ZG*, Jiang JD*.Up-regulation of glycolipid transfer protein by bicyclol causes spontaneousrestriction of hepatitis C virus replication. Acta Pharmaceutica Sinica B. 2019Jul; 9(4):769-781.

23. Wu ZY#, Li H #, Li JR, Lv XQ, Jiang JD, Peng ZG*. Farnesoid X receptoragonist GW4064 indirectly inhibits HCV entry into cells via down-regulatingscavenger receptor class B type I. Eur J Pharmacol, 2019, 15June, 853: 111-120.

24. Li H#,Tan JL#, Li JR#,Liu NN, Chen JH, Lv XQ, Zou LL, Dong B, Peng ZG *, Jiang JD *. Aproof-of-concept study in HCV-infected Huh7.5 cells for shortening the durationof DAA-based triple treatment regimens. Biomed Pharmacother. 2019 Aug; 116: 108976.

25. Li J#,Hu Y#, Hao X,Tan J,Li F,Qiao X,Chen S, Xiao C,Chen M*,Peng Z*, Gan M*.Raistrickindole A, an Anti-HCV Oxazinoindole Alkaloid from Penicilliumraistrickii IMB17-034. J Nat Prod, 2019 May24;82(5):1391-1395.